TipRanks
Advertisement
Advertisement
PMN Earnings this Week: How Will it Perform?
PremiumPre-EarningsPMN Earnings this Week: How Will it Perform?
2M ago
PMN310’s Clean Safety and Promising Biomarkers Drive Buy Rating; $35 Price Target Reiterated
Premium
Ratings
PMN310’s Clean Safety and Promising Biomarkers Drive Buy Rating; $35 Price Target Reiterated
2M ago
ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim
Premium
The Fly
ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim
2M ago
ProMIS Neurosciences initiated with a Buy at Chardan
PremiumThe FlyProMIS Neurosciences initiated with a Buy at Chardan
3M ago
Buy Rating Reiterated on PMN310’s Promising Phase 1a Data and Unchanged $18 Price Target
Premium
Ratings
Buy Rating Reiterated on PMN310’s Promising Phase 1a Data and Unchanged $18 Price Target
3M ago
ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310
Premium
The Fly
ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310
3M ago
Ram Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile
PremiumRatingsRam Selvaraju Reiterates Buy on ProMIS Neurosciences, Maintains $18 12-Month Price Target on Differentiated PMN310 Alzheimer’s Profile
4M ago
ProMIS Neurosciences shareholders approve directors and incentive plan
Premium
Company Announcements
ProMIS Neurosciences shareholders approve directors and incentive plan
5M ago
ProMIS Neurosciences initiated with a Buy at Brookline
Premium
The Fly
ProMIS Neurosciences initiated with a Buy at Brookline
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―